Biotech news for Monday, June 22, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Eoneren Shares of Denali Therapeutics ( DNLI ) spiked in the premarket on Thursday as the company announced a $195M deal to sell its rare pediatric disease priority review voucher gained from its recent FDA approval. The FDA has created the Priority Review
Canton Strategic ( CNTN ) expects to be added to the Russell 3000 Index and Russell 2000 Index after the June 26, 2026 market close. The inclusion is based on FTSE Russell’s preliminary list of additions released as part of its semi-annual index reconstitution…
Legend Biotech ( LEGN ) has announced the pricing of an underwritten public offering of 7.7M American Depositary Shares (ADSs) at a public offering price of $29.35 per ADS. Each ADS represents two of the company's ordinary shares. Total gross proceeds from
Regentis Biomaterials ( RGNT ) said Wednesday it has agreed to raise ~$6.5 million in gross proceeds through a private placement of ordinary shares and accompanying warrants with accredited and institutional investors. The company will be issuing a combination…
narvo vexar Biogen ( BIIB ) has entered into a definitive agreement to acquire private biotechnology firm RayThera Inc. in a transaction valued at up to $1B. The strategic acquisition focuses on expanding Biogen’s long-term pipeline footprint within the high-g…
fizkes Alkermes reported positive phase 2 study results of alixorexton for narcolepsy type 2 after Wednesday's market close. The Vibrance-2 trial met its dual primary endpoints: improvement from baseline compared to placebo on the Maintenance of Wakefulness Te…
Legend Biotech ( LEGN ) has commenced an underwritten public offering of $225M in American depositary shares. Each ADS represents two ordinary shares of the company. All ADSs in the offering will be issued and sold by Legend Biotech. The company plans
Biotechs hit by recent setbacks at the hands of the FDA were making a comeback on Wednesday after the FDA reversed its course on UniQure’s ( QURE ) gene therapy candidate AMT-130, paving the way for a potential accelerated nod. Regenxbio (
alexsl uniQure ( QURE ) shares climbed more than 70% during afternoon trading on Wednesday after the FDA cleared a regulatory path forward for the company's gene therapy candidate, AMT-130, prompting Cantor Fitzgerald to upgrade the stock. In a statement on We…
Zhanna Hapanovich/iStock via Getty Images The US FDA has approved GSK ( GSK ) and Spero Therapeutics' ( SPRO ) Utebzi (tebipenem pivoxil) for c omplicated urinary tract infections. The drug is the first oral carbapenem therapy approved for the condition. Effic…
Polyrizon ( PLRZ ) on Wednesday said it received notice of publication of a U.S. patent application covering its Trap & Target mucoadhesive polymer technology for nasal drug delivery. The patent application describes formulations designed to improve drug r…
Grandbrothers/iStock Editorial via Getty Images uniQure ( QURE ) shares added 78% in the premarket on Wednesday following a brief trading halt after the Dutch biotech announced its plans to submit a marketing application seeking U.S. approval for its gene ther…